Suven Pharmaceuticals Limited (NSE: SUVENPHAR)
India
· Delayed Price · Currency is INR | Market Cap | 325.73B |
| Revenue (ttm) | 9.61B |
| Net Income (ttm) | 2.43B |
| Shares Out | 254.56M |
| EPS (ttm) | 9.54 |
| PE Ratio | 134.10 |
| Forward PE | 74.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 155,316 |
| Open | 1,274.35 |
| Previous Close | 1,279.55 |
| Day's Range | 1,258.40 - 1,284.00 |
| 52-Week Range | 585.20 - 1,353.95 |
| Beta | 1.39 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 7, 2024 |
About Suven Pharmaceuticals
Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited. [Read more]
Financial Performance
In 2023, Suven Pharmaceuticals's revenue was 10.51 billion, a decrease of -21.56% compared to the previous year's 13.40 billion. Earnings were 3.00 billion, a decrease of -26.99%.
Financial StatementsNews
Suven Pharma shares surge 3% after appointment of Vivek Sharma as Executive Chairman
Suven Pharmaceuticals announced the appointment of Vivek Sharma as its new Executive Chairman, effective September 20, 2024. This move follows the transition of Vaidheesh Annaswamy, who will now serve...